No registrations found.
ID
Source
Brief title
Health condition
diabetes; NAFLD; obesity; obesitas
Sponsors and support
Maastricht University Medical Centre, Maastricht, the Netherlands
Intervention
Outcome measures
Primary outcome
fecal and intestinal microbiota composition
mucus composition, Paneth cell phenotype
Secondary outcome
body weight, BMI, abdominal circumference, composition diet, ...
Study objective
Modulation of Paneth cell and/or goblet cell function by increased lipid intake underlies the microbiota alterations that promote obesity, type 2 diabetes and non-alcoholic fatty liver disease.
Study design
Preoperative (baseline), 12 months postoperative
Intervention
Group 1: Roux-en-Y gastric bypass
Group 2: laparoscopic cholecystectomy
Group 3: upper GI endoscopy
Martine Uittenbogaart
Veldhoven 5400 DB
The Netherlands
+31408886285
m.uittenbogaart@mmc.nl
Martine Uittenbogaart
Veldhoven 5400 DB
The Netherlands
+31408886285
m.uittenbogaart@mmc.nl
Inclusion criteria
Group 1
BMI > 40 kg/m2 of >35 kg/m2 with comorbidities
Age between 18 and 60 years
Group 2 and 3
BMI 20-25 kg/m2
Age between 18 and 60 years
Exclusion criteria
Group 1
Type 1 diabetes
Alcohol or drug abuse according to DSM-V
Inflammatory disease, such as auto-immune disease
Degenerative diseases
Doctor-prescribed use of corticosteroids or prednisolon
Use of antibiotics in the three months prior to surgery
Group 2 and 3
Type 1 or type 2 diabetes
Cachexia, defined as weight loss (<5% in a month or >10% in 6 months) or a BMI <20kg/m2
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5540 |
| NTR-old | NTR5660 |
| CCMO | NL52416.015.15 |
| OMON | NL-OMON47711 |